The Type 2 Deiodinase Thr92Ala Polymorphism Is Associated with Worse Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Abstract EN

Objective.

Type 2 deiodinase (Dio2) is an enzyme responsible for the conversion of T4 to T3.

The Thr92Ala polymorphism has been shown related to an increased risk for developing type 2 diabetes mellitus (T2DM).

The aim of this study is to assess the association between this polymorphism and glycemic control in T2DM patients as marked by the HbA1C levels.

Design and Methods.

The terms “rs225014,” “thr92ala,” “T92A,” or “dio2 a/g” were used to search for eligible studies in the PubMed, Embase, and Cochrane databases and Google Scholar.

A systematic review and meta-analysis of studies including both polymorphism testing and glycated hemoglobin (HbA1C) assays were performed.

Results.

Four studies were selected, totaling 2190 subjects.

The pooled mean difference of the studies was 0.48% (95% CI, 0.18–0.77%), indicating that type 2 diabetics homozygous for the Dio2 Thr92Ala polymorphism had higher HbA1C levels.

Conclusions.

Homozygosity for the Dio2 Thr92Ala polymorphism is associated with higher HbA1C levels in T2DM patients.

To confirm this conclusion, more studies of larger populations are needed.